Musculoskeletal events associated with the management of endocrine-responsive breast cancer
Musculoskeletal symptoms have been reported in patients treated with third generation aromatase inhibitors (AIs) and with blockers of hypothalamic–pituitary gonadal axis. AIs act by suppressing postmenopausal estrogen biosynthesis through inhibition of the enzyme aromatase, which is responsible for...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2011-12-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/64 |
| _version_ | 1797966290897338368 |
|---|---|
| author | Anas Al-Janadi Borys Hrinczenko Vijay Chaudhary Shalini Chitneni Sarah Ali Jennifer Saultz Nikolay V. Dimitrov |
| author_facet | Anas Al-Janadi Borys Hrinczenko Vijay Chaudhary Shalini Chitneni Sarah Ali Jennifer Saultz Nikolay V. Dimitrov |
| author_sort | Anas Al-Janadi |
| collection | DOAJ |
| description | Musculoskeletal symptoms have been reported in patients treated with third generation aromatase inhibitors (AIs) and with blockers of hypothalamic–pituitary gonadal axis. AIs act by suppressing postmenopausal estrogen biosynthesis through inhibition of the enzyme aromatase, which is responsible for the conversion of androgens to estrogens in many tissues. Maximal estrogen and/or androgen deprivation is beneficial for cancer growth suppression but could be associated with side effects such as accelerated bone loss and osteoporotic fractures which are extensively reported. Musculoskeletal events, another group of adverse events, have been studied to a lesser extent and are usually commonly reported as arthralgia and myalgia. Furthermore, the pathogenesis and anatomical findings of musculoskeletal symptoms have not been adequately elucidated. In this communication, we review recent information related to musculoskeletal symptoms in breast cancer and speculate on possible explanations for musculoskeletal pain related to hormone deprivation. We outline treatment options for control of arthralgia and myalgia due to hormonal therapy. More knowledge about the etiology and management of musculoskeletal adverse effects breast cancer during endocrine therapy is needed because discontinuation of the treatment due to intolerant symptomatology may result in disruption of the treatment schedule. |
| first_indexed | 2024-04-11T02:13:23Z |
| format | Article |
| id | doaj.art-d9477a2e65ca4401984cd5e264d3f3af |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T02:13:23Z |
| publishDate | 2011-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-d9477a2e65ca4401984cd5e264d3f3af2023-01-03T01:49:50ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652011-12-014310.4081/oncol.2010.18559Musculoskeletal events associated with the management of endocrine-responsive breast cancerAnas Al-Janadi0Borys Hrinczenko1Vijay Chaudhary2Shalini Chitneni3Sarah Ali4Jennifer Saultz5Nikolay V. Dimitrov6Division of Hematology/Oncology, Department of Medicine, Michigan State University, B413 Clinical Center, East LansingDivision of Hematology/Oncology, Department of Medicine, Michigan State University, B413 Clinical Center, East LansingDivision of Hematology/Oncology, Department of Medicine, Michigan State University, B413 Clinical Center, East LansingDivision of Hematology/Oncology, Department of Medicine, Michigan State University, B413 Clinical Center, East LansingDivision of Hematology/Oncology, Department of Medicine, Michigan State University, B413 Clinical Center, East LansingDivision of Hematology/Oncology, Department of Medicine, Michigan State University, B413 Clinical Center, East LansingDivision of Hematology/Oncology, Department of Medicine, Michigan State University, B413 Clinical Center, East LansingMusculoskeletal symptoms have been reported in patients treated with third generation aromatase inhibitors (AIs) and with blockers of hypothalamic–pituitary gonadal axis. AIs act by suppressing postmenopausal estrogen biosynthesis through inhibition of the enzyme aromatase, which is responsible for the conversion of androgens to estrogens in many tissues. Maximal estrogen and/or androgen deprivation is beneficial for cancer growth suppression but could be associated with side effects such as accelerated bone loss and osteoporotic fractures which are extensively reported. Musculoskeletal events, another group of adverse events, have been studied to a lesser extent and are usually commonly reported as arthralgia and myalgia. Furthermore, the pathogenesis and anatomical findings of musculoskeletal symptoms have not been adequately elucidated. In this communication, we review recent information related to musculoskeletal symptoms in breast cancer and speculate on possible explanations for musculoskeletal pain related to hormone deprivation. We outline treatment options for control of arthralgia and myalgia due to hormonal therapy. More knowledge about the etiology and management of musculoskeletal adverse effects breast cancer during endocrine therapy is needed because discontinuation of the treatment due to intolerant symptomatology may result in disruption of the treatment schedule.http://www.oncologyreviews.org/index.php/or/article/view/64Breast cancer - Aromatase inhibitors - Musculoskeletal events |
| spellingShingle | Anas Al-Janadi Borys Hrinczenko Vijay Chaudhary Shalini Chitneni Sarah Ali Jennifer Saultz Nikolay V. Dimitrov Musculoskeletal events associated with the management of endocrine-responsive breast cancer Oncology Reviews Breast cancer - Aromatase inhibitors - Musculoskeletal events |
| title | Musculoskeletal events associated with the management of endocrine-responsive breast cancer |
| title_full | Musculoskeletal events associated with the management of endocrine-responsive breast cancer |
| title_fullStr | Musculoskeletal events associated with the management of endocrine-responsive breast cancer |
| title_full_unstemmed | Musculoskeletal events associated with the management of endocrine-responsive breast cancer |
| title_short | Musculoskeletal events associated with the management of endocrine-responsive breast cancer |
| title_sort | musculoskeletal events associated with the management of endocrine responsive breast cancer |
| topic | Breast cancer - Aromatase inhibitors - Musculoskeletal events |
| url | http://www.oncologyreviews.org/index.php/or/article/view/64 |
| work_keys_str_mv | AT anasaljanadi musculoskeletaleventsassociatedwiththemanagementofendocrineresponsivebreastcancer AT boryshrinczenko musculoskeletaleventsassociatedwiththemanagementofendocrineresponsivebreastcancer AT vijaychaudhary musculoskeletaleventsassociatedwiththemanagementofendocrineresponsivebreastcancer AT shalinichitneni musculoskeletaleventsassociatedwiththemanagementofendocrineresponsivebreastcancer AT sarahali musculoskeletaleventsassociatedwiththemanagementofendocrineresponsivebreastcancer AT jennifersaultz musculoskeletaleventsassociatedwiththemanagementofendocrineresponsivebreastcancer AT nikolayvdimitrov musculoskeletaleventsassociatedwiththemanagementofendocrineresponsivebreastcancer |